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Introduction
Follicle stimulating hormone (FSH) preparations are being used in the treatment of anovulatory infertility and in ovarian stimulation regimens prior to assisted reproduction technologies. With the advent of pure recombinant FSH (rFSH) it is likely that urinary preparations will be replaced by rFSH preparations. For that purpose, clinicians should gain knowledge of the main pharmacokinetic and pharmacodynamic properties of any new hormone preparation developed. The efficacy and safety of two rFSH preparations, i.e. Puregon (Organon, Oss, The Netherlands) and Gonal-F (Serono, Geneva, Switzerland), in patients undergoing ovarian stimulation have been reported since 1992 when the first pregnancies were established (Devroey et al., 1992a; Germond et al., 1992; Loumaye et al., 1995; Out et al., 1995) .
This article reviews all relevant pharmacokinetic and dynamic data of Puregon which were mainly obtained in male and female volunteers.
Pharmacokinetic study models Historical overview
The first human exposure studies of rFSH go back to early 1991, when single and multiple-rising doses were administered to gonadotrophin-deficient but otherwise healthy female and male volunteers (Schoot et al., 1992 (Schoot et al., , 1994 Matikainen et al., 1993; Shoham et al., 1993; Mannaerts et al., , 1996 . These phase I studies were performed in four specialist reproductive endocrinology and infertility units. Apart from safety and pharmacokinetic data on rFSH, these studies provided for the first time information on the pharmacodynamics of FSH in the absence of luteinizing hormone (LH) . With respect to the latter, it was found that FSH alone can induce normal follicular growth whereas FSH-induced oestrogen synthesis is impaired because of a lack of endogenous LH (Schoot et al., 1992 (Schoot et al., , 1994 Shoham et al., 1993) . Furthermore, it has been shown that the bioavailability of FSH after the administration of exogenous FSH is influenced by many factors, including gender, body weight and route of administration. Interestingly, circulating immunoreactive (I) FSH did not reflect circulating bioactive (B) FSH, in that B:I ratios of serum FSH after the administration of rFSH and urinary FSH appeared to be significantly different.
In late 1991, a phase II efficacy study was initiated in women undergoing in-vitro fertilization and embryo transfer to evaluate whether rFSH therapy could be combined with various gonadotrophin-releasing hormone (GnRH) agonist treatment regimens, inducing different degrees of pituitary suppression (Devroey et al., 1994) . The objective was to evaluate whether the amount of residual endogenous LH would be sufficient to support FSH-induced steroidogenesis and related reproductive functions. One of the first patients in this study was reported as having the first ongoing pregnancy (Devroey et al., 1992a) and singleton term birth (Devroey et al., 1992b) after ovarian stimulation with rFSH (Devroey et al., 1993) . Overall, the efficacy data indicated that rFSH stimulates multiple follicular development with corresponding rises in serum inhibin (LH-independent) and oestradiol (LH-dependent) concentrations. The rise in oestradiol concentration indicates that in women with normal menstrual cycles the amount of remaining endogenous LH after profound pituitary suppression (1-2 IU/l) is still sufficient to support rFSH-induced oestrogen biosynthesis (Devroey et al., 1994) . The outcome of this pilot efficacy study justified the further development of rFSH by means of several randomized, group-comparative, phase III studies. In parallel, dose proportionality and absolute bioavailability studies were initiated.
Interpretation of FSH activity as determined by various assays
For the detection, quantification and characterization of rFSH, three different types of assay were frequently applied, i.e. an in-vivo bioassay, an in-vitro bioassay and an immunoassay. The principles, quality controls, methodology and applications of these gonadotrophin assays have been described previously (Mannaerts et al., 1987 (Mannaerts et al., , 1991 Mason et al., 1993) . In-vivo bioassays are standard pharmacopoeia tests for the quantification of therapeutic preparations containing FSH and/or LH activity. Determining factors in these assays are gonadotrophin half-life and invivo metabolism. For the estimation of in-vivo bioactive FSH, a method developed by Steelman and Pohley (1953) was applied which measures the augmentation of ovarian weight in immature rats after 3 days of treatment with a FSH-containing preparation in the presence of a standard amount of human chorionic gonadotrophin (HCG). The suitability of this assay for pure FSH preparations, however, should be reconsidered, especially since clinical studies with rFSH have indicated that its predictive value might be limited (Out et al., 1995) .
Furthermore, because of their low sensitivity, in-vivo bioassays are unable to detect physiological amounts of gonadotrophins in body fluid samples. For the estimation of serum bioactive FSH, only in-vitro FSH bioassays are suitable which are based on the induction of FSH-specific processes in isolated target cells, i.e. granulosa or Sertoli cells. Obviously, such bioassays measure only the intrinsic bioactivity at the target level and do not take into account the elimination half-life and in-vivo metabolism. Comparative in-vitro studies for rFSH were performed in the rat Sertoli cell aromatase bioassay (Mannaerts et al., 1991) and in the human granulosa cell bioassay (Mason et al., 1993) , and serum bioactive FSH after rFSH administration was established by means of the rat granulosa cell bioassay (Matikainen et al., 1993) . Recently the human FSH receptor has been cloned (Tilly et al., 1992) and expressed in Chinese hamster ovary cells; it provides a continuous source for a homologous bioassay system and is thought to be more predictable for the actual efficacy.
To quantify the amount of circulating FSH, an immunoassay is most frequently applied. Such an assay is socalled structure specific because of the interaction of specific monoclonal antibodies with one or more antigenic epitopes. In clinical studies with rFSH, a time-resolved immunofluorometric sandwich assay (Delfia ® ) was applied which detects only intact human FSH molecules, does not crossreact with human thyroid-stimulating hormone, LH or HCG and which has a high sensitivity (detection limit 0.05 IU/l in terms of international standard 78/549). Because the antibodies in this assay, as in most immunoassays, recognize specific protein epitopes, this assay is not able to detect carbohydrate differences or alterations during clearance. Prior to the application of this assay it was confirmed that the assay recognizes the various rFSH isohormone fractions equally well because their specific immunoreactivities (specific activity per mg protein) are similar (de Leeuw et al., 1996) . In the calibration of samples, the outcome of the abovementioned assays is never the same since different properties are measured and often different references are applied because various international standards have been defined for immuno-and bioassays. These preparations are of a urinary or pituitary origin and differ in their purity and isohormone profile. For the calibration of rFSH, a first international standard of rFSH will be established within the coming year.
Models to study the pharmacokinetic properties of exogenous FSH
A proper evaluation of serum FSH concentrations after the administration of exogenous FSH requires that interference by endogenous gonadotrophins is prevented as much as possible. The pulsatile pattern of endogenous FSH is known to vary in frequency and amplitude, especially during the normal menstrual cycle when the more acidic forms of FSH in the follicular and luteal phases shift to more basic forms at the time of ovulation (Wide and Backos, 1993) . In addition, a high FSH baseline may jeopardize a proper pharmacokinetic analysis. Therefore, pharmacokinetic studies of rFSH were performed in either gonadotrophin-deficient or pituitarysuppressed volunteers. In gonadotrophin-deficient volunteers, baseline concentrations of FSH and LH were extremely low (mostly <0.5 IU/l). These subjects with hypogonadotrophic hypogonadism included cases of hypophysectomy, isolated gonadotrophin deficiency and panhypopituitarism. Because these types of patient are very rare, further pharmacokinetic studies of rFSH were performed in healthy young women with induced pituitary suppression. The degree of pituitary suppression induced by GnRH agonists can vary widely and depends on the compound of choice, and the route and frequency of administration. As an example, Figure 1 shows individual endogenous LH concentrations measured in women stimulated with rFSH and different GnRH regimens for ovarian stimulation.
Obviously, triptorelin (Decapeptyl ® ) administered once as a depot formulation, or daily via the s.c. route, seems to cause a profound suppression. In principle, compounds such as triptorelin or goserelin (Zoladex ® ) can be used for pituitary down-regulation in pharmacokinetic models (Le Cotonnec et al., 1994a,b) , but in a three-way crossover study with rFSH it was revealed that maintenance doses of 1.8 mg triptorelin administered i.m. 2, 4 and 6 weeks after the first i.m. injection of 3.75 mg triptorelin may induce considerable flare-ups of FSH and/or LH, indicating incomplete downregulation (unpublished data). For this reason, pharmacokinetic studies of rFSH were performed in women using the high-dose oral contraceptive Lyndiol ® (2.5 mg lynestrenol and 0.05 mg ethinyl oestradiol) which decreases endogenous FSH (see Figure 3) and LH concentrations to at least the same low concentrations as encountered in subjects with hypogonadotrophic hypogonadism (Out et al., 1996) . 
Pharmacokinetic properties: study outcome
The main pharmacokinetic parameters derived from serum immunoreactive FSH concentrations measured in two single-dose and two multiple-dose studies of rFSH are presented in Table I . In one single-dose study and in one multiple-dose study, a comparison was made with urinary FSH (Metrodin; Serono).
Single-dose pharmacokinetics
In gonadotrophin-deficient volunteers, who received a single i.m. injection of 300 IU rFSH in the buttock , the rate of FSH absorption was lower in women than in men, with lower peak FSH concentrations (C max ), a longer time interval to peak serum FSH concentration (t max ) and a smaller area under the serum concentration versus time curve (AUC), with the AUC tending to be smaller in women compared with men. These differences are thought to be related to the amount of gluteal s.c. fat, being greater in women than in men. Consequently, even though intended as a deep i.m. injection, women may receive part of the drug in their s.c. adipose layer, leading to slower absorption (see also below). Further studies are needed to determine this issue. Increases in serum FSH measured after the single administration of rFSH or urinary FSH are presented in Figure 2 . The calculated elimination half-life (t ½ ) of rFSH was 30-40 h and not significantly different between the sexes or between treatments. Interestingly, in both men and women a negative relationship between body weight and serum FSH concentration was revealed (r = 0.9 and 0.8 respectively). This correlation might be disturbed in normogonadotrophic subjects because of fluctuating, relatively high amounts of endogenous FSH. Nevertheless, various studies support the hypothesis that body weight is a major determining factor on the dose and duration of gonadotrophin stimulation in assisted reproduction. Further research should indicate whether the adjustment of FSH doses in relation to body weight can reduce ovarian response variability. When serum immunoreactive FSH concentrations after the administration of rFSH and urinary FSH were compared, no difference was noted for the time interval to reach peak FSH concentration; however, in both sexes it appeared that C max was significantly (P < 0.05) lower after rFSH than after urinary FSH injection. Accordingly, the AUC was significantly (P < 0.05) lower after rFSH than after urinary FSH administration. Further research showed that the lower concentrations of immunoreactive FSH after rFSH administration are not predictive for its bioactivity at the target cell level. Because of its high purity (>99%), rFSH is suitable for both i.m. and s.c. administration. The latter route is more suitable for self-administration, and its application will reduce time and the cost of medical staff. To examine whether the availability of rFSH after i.m. or s.c. injection is similar, an absolute bioavailability study of rFSH was undertaken in healthy women pituitary suppressed by the daily intake of Lyndiol. In this randomized, three-way crossover study, women received a single dose of 300 IU rFSH via the i.v., i.m. or s.c. route. Serum FSH concentrations measured after i.m. and s.c. injection are presented in Figure 3 . The absorption of s.c. administered rFSH tended to be slower, resulting in lower serum FSH concentrations during the absorption phase and in higher concentrations thereafter. Nevertheless, the extent of absorption (AUC) appeared to be equivalent and the bioavailability of the i.m. and s.c. routes in comparison with the i.v. route was almost equal, i.e. 76 and 78% respectively. Interestingly, the intersubject variability for C max after i.m. injection was much higher than after s.c. injection (coefficients of variation = 42 and 13% respectively), most probably because of the different amounts of adipose tissue and/or blood supply at the i.m. injection site.
Multiple-dose pharmacokinetics
Two multiple-dose studies of rFSH were performed, i.e. one study in gonadotrophin-deficient male and female volunteers and the other study in female volunteers pituitary suppressed by Lyndiol. In the first study, the safety of rFSH was the main objective, but in addition information on the pharmacokinetics and dynamics of rFSH was gathered. The second study focused mainly on the pharmacokinetic and pharmacodynamic properties of rFSH in comparison with those of urinary FSH (see also Table I ).
During the multiple-rising dose study of rFSH in gonadotrophin-deficient subjects, the dose was increased at weekly intervals: the first 7 days, 75 IU/day; the subsequent 7 days, 150 IU/day; and the last 7 days, 225 IU/day. Serum FSH concentrations increased in a dose-dependent manner, and steady state levels were reached after 3-5 days of treatment (Mannaerts et al., 1996) . As a typical example, the individual serum immunoreactive FSH concentration measured in three gonadotrophin-deficient men are presented in Figure 4 .
An analysis of individual steady state levels and the body weight of all male volunteers indicated a negative correlation (r = -0.6) and supports the previously revealed negative correlation between C max and body weight (r = -0.9) after single-dose administration. Accordingly, one subject weighing only 42 kg had relatively high increments of serum FSH (see also Figure 4 ). The pharmacokinetic evaluation in gonadotrophin-deficient women was hampered by the fact that four out of seven volunteers had to discontinue rFSH medication because of an increased risk of ovarian hyperstimulation (Schoot et al., 1994) . Median serum FSH steady state concentrations measured in gonadotrophin-deficient men and women prior to the first rFSH injection and 24 h after the completion of each treatment week are presented in Table II . Although the number of observations is small, especially in women, this study indicates, like the single-dose study, that the increase in serum FSH concentration is higher in men than in women, at least after deep i.m. injection in the buttock. In accordance with the protocol, four out of seven female volunteers were discontinued during rFSH treatment because at least one follicle >14 mm in diameter was observed by ultrasonography. The design of a group-comparative, randomized, multiple-dose study of rFSH in pituitary-suppressed healthy women of reproductive age is given in Table III . The pharmacokinetic outcome of this study is included in Table I . Steady state was reached after four doses of FSH for all groups. The dose-normalized C min just before the last injection was comparable between groups, indicating dose proportionality in the 75-225 IU dose range. Immunoreactive serum FSH concentrations measured 24 h after each injection of 150 IU rFSH and 150 IU urinary FSH were similar.
Pharmacokinetic versus pharmacodynamic properties
As explained above, immunoassays only indicate the amount of intact FSH molecules present in the circulation and do not reflect the extent to which these molecules bind to the FSH receptor and are able to trigger target cells. In comparative pharmacokinetic studies of rFSH, in which equal doses of in-vivo bioactive FSH were administered, the amount of immunoreactive FSH after a single dose of rFSH was significantly lower than after a comparable dose of urinary FSH. Whether differences in serum immunoreactive FSH concentrations are predictive for the magnitude of ovarian response depends on the bioactivity of circulating FSH glycoforms. The latter can only be measured by an in-vitro bioassay, which was also applied in the single-dose study of rFSH in gonadotrophin-deficient volunteers. For this purpose, serum samples taken prior to recombinant or urinary FSH injection, and taken 6, 24 and 72 h thereafter, were analysed in both the immunofluorometric assay and the in-vitro granulosa cell bioassay (Matikainen et al., 1993) . The calculated ratio of the outcome of these assays, called the B:I ratio, is presented in Table IV .
In all subjects, endogenous bioactive FSH measured in pretreatment samples was under the detection limit of the bioassay (~3.7 IU/I). Individual B FSH concentrations measured at 6, 24 and 72 h after rFSH or urinary FSH administration were undetectable at all time points in one woman (body weight 85.8 kg) who was excluded from further evaluation. In all subjects treated with rFSH, B FSH was measurable for at least 72 h; during this period, no significant changes in the B:I ratio occurred. In addition, there was no significant difference in the B:I ratio between men and women. The B FSH concentrations after rFSH treatment tended to be higher than those after urinary FSH treatment, whereas the I FSH concentration showed an opposite tendency. As a result, in all post-treatment samples the B:I ratio was significantly higher after rFSH treatment than after urinary FSH treatment. This obviously clinically relevant difference will have to be confirmed in similar studies comprising larger numbers of patients. Whether the higher serum B:I ratio of rFSH results in a greater ovarian response was established in the comparative multiple-dose study of rFSH in women pituitary suppressed by Lyndiol (Table III) . Ovarian response was monitored daily by ultrasonography. A daily dose of 75 IU rFSH, given for 7 days, appeared to be too low to induce significant follicular growth (diameter of at least 10 mm) in any of the nine volunteers. In contrast, follicular growth was induced in all other subjects treated with 150 or 225 IU rFSH or 150 IU urinary FSH. The total number and size of follicles induced by 150 IU rFSH and 150 IU urinary FSH are depicted in Figure 5 .
The difference in number and size distribution indicates the higher efficacy of rFSH in terms of inducing multiple follicular growth. This observation is in agreement with the higher B:I ratio of rFSH. Because rFSH contains more relatively basic isoforms and less relatively acidic isoforms than urinary FSH (de Leeuw et al., 1996) , and because basic isoforms are known to have a higher receptor affinity and intrinsic bioactivity than acidic isoforms, these findings may indicate that the relatively short-living basic FSH isoforms play an important role in the induction of (multiple) follicular growth, whereas the longer-living acidic FSH isoforms provide a certain maintenance of FSH above the required threshold. In comparison with other preparations, rFSH might trigger the ovary to a greater extent, especially during the first hours after injection. The ovarian response is modulated by various endocrine and paracrine factors like LH, GnRH, inhibin, activin, insulin and insulin-like growth factors. The role of LH during the induction of follicular growth was established in gonadotrophin-deficient women treated with multiple-rising doses of rFSH (Schoot et al., 1994) , which is devoid of any LH activity. The study design and steady state concentrations of serum FSH in these women have been described above. Interestingly, in hypogonadotrophic women, rFSH induced the normal growth of (multiple) ovarian follicles up to pre-ovulatory sizes (>15 mm), whereas only minor increases in serum oestradiol concentrations were observed because of the low availability of androgens. These data suggest a differential regulation of mitogenic and steroidogenic granulosa cell activity by FSH. Moreover, oestrogens appear to be less mandatory for human follicle development than previously believed. In accordance with the impaired oestrogen synthesis during ovarian stimulation in gonadotrophin-deficient women, women pituitary suppressed by Lyndiol also had normal follicular growth without or with only minor rises in serum oestradiol concentration.
Conclusions
In pharmacokinetic studies, the amount of serum immunoreactive FSH is not only determined by the dose of exogenous FSH, but also by the body weight, gender and route of administration. After the administration of equal doses of in-vivo bioactive FSH, the amount of serum immunoreactive FSH might be significantly different between FSH preparations because of differences in their isohormone profiles. This may also explain why even though serum immunoreactive FSH concentrations are lower or equal, the actual bioactivity of this circulating FSH can be higher. Therefore, the conventional idea that serum immunoreactive FSH correlates positively with the magnitude of ovarian response should be reconsidered. It is suggested that relatively basic isohormones, because of their higher intrinsic bioactivity, play an important role in the induction of multiple follicular growth.
